The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SYN | -81.63% | -99.74% | -69.61% | -100% |
| S&P | +13% | +86.41% | +13.26% | +395% |
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 15.2% |
| Market Cap | $3.89M | 108.1% |
| Market Cap / Employee | $0.18M | 0.0% |
| Employees | 22 | 0.0% |
| Net Income | -$4.36M | 43.6% |
| EBITDA | -$4.41M | 11.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.53M | -54.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.09M | 84.2% |
| Short Term Debt | $0.68M | 11.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -73.83% | -21.3% |
| Return On Invested Capital | -70.37% | -5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.34M | -10.9% |
| Operating Free Cash Flow | -$4.32M | -10.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.19 | 0.16 | 0.08 | 0.35 | 624.32% |
| Price to Tangible Book Value | 0.77 | 1.79 | -0.47 | -0.41 | -273.34% |
| Enterprise Value to EBITDA | 1.18 | 0.94 | 1.59 | 0.19 | -92.68% |
| Return on Equity | -87.3% | -100.0% | -154.5% | -167.0% | 114.29% |
| Total Debt | $1.57M | $2.86M | $2.89M | $2.76M | 58.83% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
